Fair Value Measurements - Narrative (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	May 03, 2023
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Payments related to the settlement of the contingent consideration liability, Financing activities	$ 3,569,000	$ 32,918,000	$ 10,665,000
Payments related to the settlement of the contingent consideration liability, Operating activities	12,800,000	1,800,000
Impairment of equity method investment	0	0
Impairment of intangible assets	$ 0	$ 1,700,000	$ 1,600,000
Impairment, Intangible Asset, Finite-Lived, Statement of Income or Comprehensive Income [Extensible Enumeration]	Asset Impairment Charges	Asset Impairment Charges	Asset Impairment Charges
(Gain) Loss on disposition of business	$ (431,000)	$ 1,417,000
Impairment loss on operating lease asset	0	0	$ 1,400,000
Interest income	2,456,000	439,000	769,000
Investments in privately held companies	19,061,000	15,576,000
Impairment of property and equipment	0	0
Long-term notes receivable, net	3,241,000	2,397,000
Allowance for expected credit losses	568,000	281,000	199,000
XableCath
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Impairment of equity method investment		500,000
Bluegrass Vascular Technologies, Inc
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Impairment of equity method investment	300,000
Ownership percentage				19.50%
Equity method investment				$ 245,000
STD Pharmaceutical Products Limited
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Impairment of intangible assets		$ 1,700,000
Impairment, Intangible Asset, Finite-Lived, Statement of Income or Comprehensive Income [Extensible Enumeration]		Asset Impairment Charges
Selio
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Long-term notes receivable, net	3,200,000	$ 2,400,000
Allowance for expected credit losses	568,000	281,000
ArraVasc Limited
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Impairment of intangible assets			$ 1,600,000
Impairment, Intangible Asset, Finite-Lived, Statement of Income or Comprehensive Income [Extensible Enumeration]			Asset Impairment Charges
Impairment of property and equipment			$ 1,300,000
Impairment, Long-Lived Asset, Held-for-Use, Statement of Income or Comprehensive Income [Extensible Enumeration]			Asset Impairment Charges
Director | Cianna Medical
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent payments related to acquisition	900,000	1,600,000	$ 0
Other long-term obligations
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration liability, noncurrent	3,000,000.0	2,300,000
Accrued expenses
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration liability, current	$ 400,000	$ 15,800,000